>A solid Q1, slightly above expectations - This morning, Daimler Truck reported Q1 results that came in slightly ahead of expectations. Q1 revenues were € 13.3bn, flat y-o-y (vs company-compiled cons. at € 13.0bn, ODDO BHF € 12.7bn), driven by a strong price/mix as volumes (already reported) were down -13% y-o-y to 109k units. Adj. EBIT was € 1.21bn, +4% y-o-y, i.e. a margin of 9.1%, +30bps y-o-y, slightly ahead of expectations (css € 1.17bn, ODDO BHF € 1.16bn). Lastl...
>A solid Q1, slightly above expectations - This morning, Daimler Truck reported Q1 results that came in slightly ahead of expectations. Q1 revenues were € 13.3bn, flat y-o-y (vs company-compiled cons. at € 13.0bn, ODDO BHF € 12.7bn), driven by a strong price/mix as volumes (already reported) were down -13% y-o-y to 109k units. Adj. EBIT was € 1.21bn, +4% y-o-y, i.e. a margin of 9.1%, +30bps y-o-y, slightly ahead of expectations (css € 1.17bn, ODDO BHF € 1.16bn). Lastl...
Euronext upgraded to ‘BBB+, Positive Outlook‘ by S&P Contacts Media Contact Investor Relations Amsterdam Brussels 27 Dublin 13 Lisbon 4 Milan 12 Oslo Paris 45 Euronext upgraded to ‘BBB+, Positive Outlook‘ by S&P Amsterdam, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 30 April 2024 – Euronext, the leading pan-European market infrastructure, today welcomes the decision of S&P to upgrade Euronext from ‘BBB+, Stable Outlook’ to ‘BBB+, Positive Outlook’. S&P decision reflects the approaching completion of the integration of the Borsa Italia...
Having flirted with the 495-point mark on Friday, which could have triggered an extension of the correction, the market has rebounded well since then. Our technical analysis highlights a configuration in which we are only at the start of a powerful rally. Target of 622 points for Stoxx 600 index (+11%) by the end of the year confirmed. Prefer banks to insurance companies in the short term. - ...
Après avoir frôlé vendredi la barre des 495 points qui aurait pu déclencher la poursuite de la correction, le marché a ensuite bien rebondi. Notre analyse technique met en lumière une configuration où nous ne serions qu’au début d’un rallye puissant. Objectif 622 points (+11%) d’ici à la fin de l’année confirmé sur le Stoxx 600. Préférer les banques aux assurances à court terme. - ...
>Group sales of € 1,292m in Q1 2024, in line with consensus - Symrise reported group sales of €1,292m in Q1 2024, in line with the consensus forecast of € 1,282m (ODDO BHF € 1,273m) and up 5% y-o-y with a 5.6% FX headwind weighing. Organic growth of 10.9% y-o-y was ahead of the consensus at 9.1% (ODDO BHF 8.3%) and compares to the Q4 2023 level of 9.5%, but includes a 4pp FX-based pricing (Argentina) component baked into -1% price vs +11.9% volume against a light comp...
EQS-News: Symrise AG / Schlagwort(e): Quartals-/Zwischenmitteilung/Umsatzentwicklung Symrise startet erfolgreich in das Geschäftsjahr 2024 (News mit Zusatzmaterial) 25.04.2024 / 07:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Umsatzentwicklung Januar - März 2024 Holzminden, 25. April 2024 Symrise startet erfolgreich in das Geschäftsjahr 2024 — Organisches Wachstum von 10,9 % — Umsatzwachstum von 5,0 % in Berichtswährung — Konzernumsatz steigt auf 1,3 Mrd. € im ersten Quartal — Ziele 2024 und Langfristziele bis 202...
EQS-News: Symrise AG / Key word(s): Quarterly / Interim Statement/Development of Sales Symrise sees successful start into the 2024 fiscal year (news with additional features) 25.04.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Trading Update, January – March 2024 Holzminden, Germany, April 25, 2024Symrise sees successful start into the 2024 fiscal year — Organic growth of 10.9 % — Sales growth of 5.0 % in reporting currency — Group sales increase to € 1.3 billion in the first quarter — 2024 targets and long-term targets thro...
BioNTech veröffentlicht am 6. Mai 2024 Ergebnisse für das erste Quartal 2024 und informiert über operativen Fortschritt MAINZ, Deutschland, 22. April 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird am Montag, den 6. Mai 2024, die Ergebnisse für das erste Quartal 2024 veröffentlichen. Darüber hinaus wird das Unternehmen am selben Tag um 14:00 Uhr MESZ (8:00 Uhr Eastern Daylight Time) eine Telefonkonferenz samt Webcast für Investoren, Finanzanalysten sowie die allgemeine Öffentlichkeit durchführen, um die Finanzergebnisse sowie ein Unternehmensupdate zu präsen...
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024 MAINZ, Germany, April 22, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2024 on Monday, May 6, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (2:00 p.m. CEST) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. To access the live conference call via telephone, please register via this . Once reg...
Euronext announces volumes for March 2024 Contacts Media Contact Investor Relations Amsterdam Brussels 17 Dublin 13 Lisbon 97 Milan 56 Oslo Paris 45 Euronext announces volumes for March 2024 Amsterdam, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 8 April 2024 – Euronext, the leading pan-European market infrastructure, today announced trading volumes for March 2024. Monthly and historical volume tables are available at this address: CONTACTS MEDIA – Europe A...
Drei-Jahres-Follow-up-Daten aus Phase-1-Studie mit individualisiertem mRNA-Immuntherapie-Kandidaten zeigen eine anhaltende Immunantwort und ein verringertes Rückfallrisiko bei einigen Patienten mit reseziertem Bauchspeicheldrüsenkrebs Drei-Jahres-Follow-up-Daten aus einer nichtkommerziellen Phase-1-Studie mit dem individualisierten mRNA-basierten Krebsimpfstoff-Kandidaten Autogene Cevumeran (BNT122, RO7198457) bei Patientinnen und Patienten mit chirurgisch entferntem, duktalem Adenokarzinom der Bauchspeicheldrüse (pancreatic ductal adenocarcinoma, „PDAC“) zeigen weiterhin polyspezifische T-...
Euronext to acquire Global Rate Set Systems to strengthen its index franchise Contacts Media Contact Investor Relations Amsterdam Brussels 17 Dublin 13 Lisbon 4 Milan 12 Oslo Paris 45 Euronext to acquire Global Rate Set Systems to strengthen its index franchise Amsterdam, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 29 March 2024 – Euronext, the leading pan-European market infrastructure, today announces that it has entered into an agreement to acquire 75% of the share capital of Global Rate Set Systems (GRSS), a leading provider of ser...
Euronext publishes its 2023 Universal Registration Document Contacts MediaContact Investor RelationsAmsterdam Brussels 17Dublin 13Lisbon 4 Milan 12Oslo Paris 45 Euronext publishes its 2023 Universal Registration Document Amsterdam, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 28 March 2024 – Euronext, the leading pan-European market infrastructure, today announces that it has filed its 2023 Universal Registration Document, prepared in ESEF format (European Single Electronic Format), including the 2023 Annual Financial Statements and Directors’ Report to the Stichting Autoriteit...
Convening of the Annual General Meeting of Euronext N.V. Contacts MediaContact Investor RelationsAmsterdam Brussels 17Dublin 13Lisbon 4 Milan 12Oslo Paris 45 Convening of the Annual General Meeting of Euronext N.V. Amsterdam, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 28 March 2024 – Euronext today announced that the Annual General Meeting (“AGM”) will take place on Wednesday 15 May 2024 at 10.30 CEST at Beursplein 5, 1012 JW Amsterdam, The Netherlands. The agenda for the meeting is as follows: Opening Presentation of the Chief Executive Officer (discussion item)Annual rep...
After very strong results during 2021 and 2022 on the back of industry tailwinds due to supply chain disruptions, IMCD maintained a relatively steady operating performance over 2023 despite a clear normalisation of end-market demand within Industries. Notwithstanding these industry pressures, IMCD was able to offset the negative organic growth over 2023 (-6.4%) with its acquisitory power, stabilising growth for the year (excl. FX impact). We believe that IMCD is ready to resume its up...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.